Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
BörsenkürzelOGN
Name des UnternehmensOrganon & Co
IPO-datumMay 14, 2021
CEOMorrissey (Joseph T)
Anzahl der mitarbeiter10000
WertpapierartOrdinary Share
GeschäftsjahresendeMay 14
Addresse30 Hudson Street
StadtJERSEY CITY
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl07302
Telefon15514306000
Websitehttps://www.organon.com/
BörsenkürzelOGN
IPO-datumMay 14, 2021
CEOMorrissey (Joseph T)